Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds

Patent metadata

Field	Value
Publication number	US-11840495-B2
Application number	US-202117560997-A
Country	US
Kind code	B2
Filing date	Dec 23, 2021
Priority date	Dec 23, 2020
Publication date	Dec 12, 2023
Grant date	Dec 12, 2023

Abstract

The present disclosure relates to compositions and methods related to bicyclo[2.2.1] heptanamine-containing compounds and salts.

First claim

We claim:

1. A compound having a structure represented by formula IVo:

or a stereoisomer or pharmaceutically acceptable salt thereof, wherein:
R 1A is ethyl and R 1B is C 1-6 alkyl, C 2-6 alkenyl, or C 2-6 alkynyl; or
R 1A is methyl and R 1B is ethyl;
wherein R 1A and R 1B are each independently and optionally substituted with 1, 2, 3, 4, 5, or 6 deuterium or halogen atoms;
both instances of R 3 are H or are C 1-6 alkyl.

2. The compound of claim 1 , wherein both instances of R 3 are H.

3. The compound of claim 1 , wherein both R 1A and R 1B are ethyl.

4. The compound of claim 1 , wherein R 1A is methyl.

5. The compound of claim 1 , wherein R 1A is ethyl.

6. The compound of claim 1 , wherein R 1A is methyl and R 1B is ethyl.

7. The compound of claim 1 , wherein R 1A and R 1B are each independently substituted with 1, 2, or 3 deuterium or halogen atoms.

8. The compound of claim 1 , wherein R 1A and R 1B are each unsubstituted.

9. The compound of claim 1 , wherein the compound is represented by formula VIa or VIb:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 , wherein the compound is represented by formula VIc or VId:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 1 , wherein the compound is represented by formula VIe or VIf:

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 1 , wherein the compound is represented by formula VIg or VIh:

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein the compound is represented by formula VIi or VIj:

or a pharmaceutically acceptable salt thereof.

14. A compound selected from:

or a pharmaceutically acceptable salt thereof.

15. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

16. A method of treating a disorder selected from a MUC1-associated kidney disease, retinitis pigmentosa, or a uromodulin kidney disease, in a subject in need thereof, comprising administering to the subject a compound of claim 1 , or a pharmaceutically acceptable salt thereof.

Assignees

• Broad Inst Inc
• Inst Carlos Slim De La Salud A C
• Brigham & Womens Hospital Inc
• Brigham & Womens Hospital Inc

Inventors

• Chamberlain Brian T
• Kornfilt David
• Wagner Florence F
• Alimova Maria
• Greka Anna
• Growney Joseph

Classifications

• C07C211/38 Primary

  containing condensed ring systems · CPC title

• A61P13/12 Primary

  of the kidneys · CPC title

• C07C209/22

  by substitution of other functional groups · CPC title

• C07C215/44

  bound to carbon atoms of the same ring or condensed ring system · CPC title

• C07C217/52

  having etherified hydroxy groups or amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton · CPC title